

**Oklahoma Health Care Authority**  
**Drug Utilization Review Board**  
(DUR Board)  
**Meeting –March 13, 2013 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. February 14, 2013 DUR Minutes – Vote
  - B. February 14, 2013 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Medication Coverage Activity for February 2013
  - B. Pharmacy Help Desk Activity for February 2013
  - C. SoonerCare Atypical Rx Program Update

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Chronic Obstructive Pulmonary Disease Medications – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

6. **Action Item - Vote to Prior Authorize Select Oral Corticosteroid Medications – See Appendix D.**
  - A. COP Recommendations
  - B. Utilization Details

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Diabetes Medications and 30 Day Notice to Prior Authorize Juvisync<sup>®</sup>, Bydureon<sup>®</sup>, Jentaduetto<sup>®</sup>, Janumet XR<sup>®</sup>, Nesina<sup>®</sup>, Kazano<sup>®</sup>, and Oseni<sup>®</sup> – See Appendix E.**
  - A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Update
  - E. Cost Comparisons
  - F. COP Recommendations
  - G. Utilization Details
  - H. Product Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

8. **Action Item –Annual Review of Anticoagulant Medications and 30 Day Notice to Prior Authorize Eliquis<sup>®</sup> – See Appendix F.**
  - A. Current Authorization Criteria
  - B. Utilization Review
  - D. Prior Authorization Review
  - E. Market News and Update
  - F. COP Recommendations
  - G. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **30 Day Notice to Prior Authorize Kuvan<sup>®</sup> – See Appendix G.**
  - A. Introduction and Product Summary
  - B. COP Recommendations
  - C. Product Details

Items to be presented by Dr. Le, Dr. Moore, Dr. Muchmore, Chairman

10. **30 Day Notice to Prior Authorize Gattex<sup>®</sup> – See Appendix H.**
  - A. Introduction and Product Summary
  - B. Cost Comparison
  - C. COP Recommendations
  - D. Product Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**
12. **Future Business**
  - A. Fiscal Year 2012 Review
  - B. New Product Reviews
  - C. Annual Reviews
13. **Adjournment**